Ri-qiang Liao
106 Zhongshan 2nd Road
Guangzhou, 510080, China
Guangzhou, 510080, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant non-small cell lung cancer (NEOTIDE/CTONG2104): phase II trial and correlative genomic analysis in China.
Journal: EClinicalMedicine
Published: January 25, 2026
Adjuvant immunotherapy may have no impact on survival in patients who received neoadjuvant immunotherapy for stage II-IIIB non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 18, 2026
LAMPAD: An Integrated Circulating Tumor DNA-Based Model for Predicting Potential Cure in Patients With Resected NSCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: December 21, 2025
Neoadjuvant afatinib in a patient with locally advanced lung adenocarcinoma harboring an NPTN-NRG1 fusion: a case report.
Journal: World journal of surgical oncology
Published: November 24, 2025
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
Journal: JAMA oncology
Published: June 13, 2024
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).
Journal: Cell reports. Medicine
Published: November 02, 2023
Impact of preoperative [18F]FDG PET/CT vs. contrast-enhanced CT in the staging and survival of patients with clinical stage I and II non-small cell lung cancer: a 10-year follow-up study.
Journal: Annals of nuclear medicine
Published: October 14, 2023
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study.
Journal: Signal transduction and targeted therapy
Published: May 24, 2023
Deep learning-based growth prediction for sub-solid pulmonary nodules on CT images.
Journal: Frontiers in oncology
Published: July 25, 2022
PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma.
Journal: Frontiers in immunology
Published: May 24, 2022
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial.
Journal: Signal transduction and targeted therapy
Published: May 03, 2022
Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer.
Journal: Cancer discovery
Published: December 14, 2021
Last Updated: 09/26/2026